Last reviewed · How we verify

Epinephrine inhalation

Amphastar Pharmaceuticals, Inc. · FDA-approved active Small molecule

Epinephrine inhalation is a bronchodilator that stimulates alpha and beta-adrenergic receptors to rapidly relieve acute bronchospasm and airway obstruction.

Epinephrine inhalation is a bronchodilator that stimulates alpha and beta-adrenergic receptors to rapidly relieve acute bronchospasm and airway obstruction. Used for Acute bronchospasm and croup in pediatric patients, Emergency relief of acute airway obstruction.

At a glance

Generic nameEpinephrine inhalation
Also known asoxymetazoline lidocaine
SponsorAmphastar Pharmaceuticals, Inc.
Drug classAdrenergic agonist bronchodilator
TargetAlpha-1, beta-1, and beta-2 adrenergic receptors
ModalitySmall molecule
Therapeutic areaPulmonology / Respiratory
PhaseFDA-approved

Mechanism of action

Epinephrine acts as a non-selective adrenergic agonist, binding to alpha-1, beta-1, and beta-2 adrenergic receptors. When inhaled, it rapidly reaches the airways where beta-2 receptor stimulation causes bronchial smooth muscle relaxation and bronchodilation, while alpha-1 stimulation reduces mucosal edema. This dual action provides rapid symptomatic relief of acute airway obstruction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results